Key Takeaways HealthEquity Q2 EPS of $1.08 beat estimates and rose 25.6% Y/Y, with GAAP EPS up 70% Y/Y.Quarterly revenues grew 8.6% to $325.8M, driven by gains in custodial and interchange revenues.Total HSA assets hit $33.1B, up 12% Y/Y, with 10M HSAs and 782,000 invested accounts reported.HealthEquity, Inc. (HQY) reported adjusted earnings per share (EPS) of $1.08 for second-quarter fiscal 2026, surpassing the Zacks Consensus Estimate by 17.4%. The bottom line improved 25.6% on a year-over-year basis.GAAP ...

Tenet Healthcare (THC) FY 2025 Conference September 03, 2025 09:30 AM ET Company ParticipantsWilliam McDowell - VP - IRSaum Sutaria - Chairman & CEOSun Park - EVP & CFOConference Call ParticipantsStephen Baxter - Senior Equity Research AnalystStephen BaxterOkay, perfect. All right. Good morning, everyone. Thanks for joining us. I'm Steve Baxter, the Healthcare Services Analyst here at Wells Fargo. We're very pleased to have Tenet Healthcare with us this morning. As you likely know, Tenet operates a network ...

【解剖大盘】 今天大阅兵，开始市场还挺兴奋，恒指一度往上冲高，但后面便一路走弱，收盘反跌0.60%。 对于此次的阅兵，可以说非常震撼，因为展示了国之重器："惊雷-1"空基远程导弹、"巨浪-3"潜射洲际 导弹、"东风-61"陆基洲际导弹，还有"东风-5C"液体洲际战略核导弹，这是我国战略反击体系中的重要 组成，打击范围覆盖全球。这是首次集中展示我军陆、海、空基"三位一体"战略核力量。这些利器最厉 害的地方在于可以优势互补，形成"二次核打击"能力，这意味着谁敢贸然对我们发动核攻击，那么必然 会遭受反噬，因为有二次反击能力。有了威慑力量，就意味着安全有了保障。再也没有哪个国家敢说从 实力的地位出发这种言论。 常规武器就不用说了，全球第一种带相控阵雷达的无人炮塔坦克、全球第一款投入实战的激光炮、全球 第一款超音速智能无人机、无限航程的核鱼雷、最新式的具备打击星链的防空导弹、完整的打击无人机 的多层防空武器、高能激光武器等等，六代机还没有展示，更关键是，能展示出来的都不算最先进的， 起码还有两代以上的产品储备，我们的目标是星辰大海。 全球都在关注大阅兵，五角大楼附近的达美乐披萨店和棒约翰披萨店流量激增，分别是平时的4倍 ...

证券日报网讯 9月3日晚间，国际医学（000516）发布公告称，公司将于2025年9月8日召开2025年第一 次临时股东会。本次股东会将审议《关于修改〈公司章程〉的议案》等多项议案。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688222 | 成都先导 | 28.80 | 13.74% | 48.52万 | | 13.39 Z | | 600721 | 自花医药 | 10.42 | 10.03% | 36.46万 | | 3.70亿 | | 300363 | 博腾股份 | 26.71 | 7.36% | 62.79万 | | 16.74亿 | | 300143 | 盈康生命 | 11.97 | 4.36% | - 43.55万 | | 5.11亿 | | 688131 | 皓元医药 | 70.49 | 4.14% | 9.33万 | | 6.53亿 | | 002622 | 皓宸医疗 | 3.94 | 3.96% | 70.65万 | | 2.74亿 | | 603127 | 昭衍新药 | 33.42 | 3.47% | 50.22万 | | 16.89 Z | | 688621 | 阳光诺和 | 76.80 | 2.54% | 4.36万 | | 3. ...

Group 1 - The stock price of Haocen Medical (002622) closed at 3.94 yuan on September 3, 2025, with an increase of 3.96% and a trading volume of 706,500 hands, resulting in a transaction amount of 274 million yuan [1] - On September 3, 2025, the net inflow of main funds was 8.9685 million yuan, accounting for 3.27% of the total transaction amount, while retail investors experienced a net outflow of 36.7847 million yuan, representing 13.42% of the total transaction amount [1] - The company's main business includes oral medical services and the research, production, and sales of permanent magnet switches and complete sets of high and low voltage switchgear [2] Group 2 - Haocen Medical's total market value is 3.31 billion yuan, with a net asset of 408 million yuan and a net profit of -23.7511 million yuan, ranking 37th, 39th, and 36th respectively in the medical service industry [2] - The company's revenue for the first half of 2025 was 314 million yuan, a year-on-year decrease of 17.9%, while the net profit attributable to shareholders was -23.7511 million yuan, a year-on-year decline of 4391.18% [2] - The gross profit margin of Haocen Medical is 43.16%, which is higher than the industry average of 35.92%, while the net profit margin is -11.04%, significantly lower than the industry average of 3.8% [2]

Core Perspective - Tianjin is positioning itself as a key hub for international trade and cultural exchange, leveraging its geographical advantages and historical significance to foster high-level openness and quality development [1][2]. Group 1: Economic Development and Trade - Tianjin Port serves as a crucial gateway for trade, maintaining connections with over 500 ports in more than 180 countries and regions, highlighting its role in China's global trade network [2][3]. - In the first seven months of this year, Tianjin's total import and export volume with Shanghai Cooperation Organization (SCO) countries exceeded 53.3 billion yuan, marking a year-on-year increase of 5.2%, with exports alone reaching over 41.7 billion yuan, up by 9.9% [3]. Group 2: Foreign Investment and Cooperation - Tianjin has attracted significant foreign investment, exemplified by the establishment of the first wholly foreign-owned tertiary hospital in China, which aims to meet high standards in healthcare services [4]. - The "Teda Model" from Tianjin is being replicated in the China-Egypt Suez Economic and Trade Cooperation Zone, showcasing Tianjin's experience in industrial cooperation and urban integration [5]. Group 3: Innovation and Technology - Tianjin is focusing on technological innovation to drive economic growth, with companies like Tianjin Yi Technology Co., Ltd. collaborating internationally to provide advanced solutions in water resource management [7]. - The Tianjin High-tech Service Industry has seen revenue growth of 16.1%, while strategic emerging service industries grew by 17.4% in the first five months of this year, indicating a robust innovation ecosystem [8]. Group 4: Urban Development and Governance - Tianjin is actively enhancing its urban environment in preparation for the 2025 SCO Summit, focusing on city beautification and modernization efforts [11][12]. - The city has implemented smart city initiatives, integrating data from various departments to improve urban management and service delivery [13]. Group 5: Environmental Sustainability - Tianjin is committed to green development, with 243 national-level green manufacturing units and initiatives to optimize energy structures and reduce carbon emissions [9][10]. - The city has achieved a solid track record in waste utilization and carbon market compliance, reflecting its dedication to sustainable practices [10].

2025H1收入、归母净利润、扣非归母净利润同比增速分别达到-2.05%、4.69%、0.86%，增速有所波 动，可能是由 于科伦药业、复星医药等仿制药业务阶段性波动导致。 业绩回顾：整体增长承压，寻找结构亮点 生物医药：全板块营收同比下滑，降幅较Q1收窄 2025年Q1，医药行业全板块营业收入同比下降4.50%；2025年上半年，医药行业全板块营业收入同比下 降3.06%，降幅 较Q1收窄。 2025年Q1 ，医药行业全板块扣非归母净利润同比下降9.60%；2025年上半 年，医药行业全板块扣非归母净利润同比下 降12.50%，降幅还在加大。 2025年上半年，CRO/CMO、医疗服务、家用器械和高值耗材板块呈现收入和扣非归母净利润的双重增 长。 就扣非增速排名的变化来看，CRO/CMO、生物制剂上游、家用器械、医疗零售、医疗设备、医疗信息 化增速排 名有所上升，上升较快的是生物制药上游和家用器械。 化学制药：创新药保持增长，仿制药短期承压 化学制药：创新药保持增长，仿制药持续消化 宏观环境及高基数影响，24年行业承压。24年行业头部企业陆续消化大订单带来的人员、产能冗余，对 内积极提质增效， 对外持续开拓 ...

中国经济网北京9月3日讯 两市高开低走，截至今日午间收盘，上证综指报3820.98点，跌幅0.96%；深证成 指报12474.44点，跌幅0.63%；创业板指报2872.12点，平收。 A股市场板块涨跌幅排行 | 序号 | 板块 | 涨跌幅(%)▼ | 总成交量 (万手) = 总成交额 (亿元) ▼ | | 净流入 (亿元) ▼ | 上涨家数 | 下跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 游戏 | 1.42 | 940.11 | 173.66 | 9.65 | 19 | ന | | 2 | 影视院线 | 1.02 | 628.13 | 47.51 | -1.36 | ਰੇ | 11 | | 3 | 电子化学品 | 0.89 | 775.46 | 148.71 | 8.19 | 24 | 15 | | ব | 非金属材料 | 0.52 | 84.33 | 22.90 | -1.16 | 5 | 8 | | 5 | 音受星 | 0.40 | 781.85 | 144.63 | -9.73 | র্ম | 6 | | 6 | 半島体 ...

齐鲁晚报.齐鲁壹点于佳霖通讯员李成修马瑾 眼动脉段动脉瘤堪称颅内动脉瘤中的"棘手角色"，它紧邻视神经、颈内动脉等关键结构，位置十分特殊。以往，传统开颅手术不仅创伤大，而且手术风险 极高；而普通的支架辅助栓塞治疗，又常常因为瘤颈宽大、形态不规则等问题，导致动脉瘤复发率居高不下。 血流导向装置的出现，为解决这一难题带来了转机。它依据"血流重塑"的原理，通过在载瘤动脉内放置一种高密度的密网支架，能够显著减少流入瘤腔的 血流，进而促进瘤内血栓形成和内皮化，最终实现动脉瘤的治愈。 吴鑫(左四)与张震(左一)团队围绕患者病情沟通治疗方案 "与传统治疗相比，血流导向装置无需直接填塞瘤腔，尤其适合大型、巨大型或梭形动脉瘤，且长期动脉瘤闭塞率更高。"吴鑫主任医师介绍道，"在本次 治疗的病例中，就包括了一例眼动脉多发动脉瘤，术后造影清晰显示血流导向效果显著，患者的神经功能丝毫未受影响。" 微创治疗让患者快速康复 接受治疗的这位62岁女性患者，因突发头痛就医，检查后发现患有2枚眼动脉段动脉瘤，且载瘤动脉局部还有动脉硬化样改变，动脉瘤随时有破裂的风 险。 近日，烟台毓璜顶医院血管神经外科团队成功为一名62岁的眼动脉段多发动脉瘤患者实 ...